SCHEMBL6744187

SCHEMBL6744187

COc1ccc(CNC(=O)c2ccc3c(c2)SC(Cc2ccco2)C(=O)N3C)cc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GFER P55789 1/20 0.47
ALDH1A1 P00352 7/20 0.46
MAPT P10636 3/20 0.46
LMNA P02545 2/20 0.46
POLB P06746 1/20 0.46
GAA P10253 1/20 0.46
DRD2 P14416 2/20 0.46
HSD17B10 Q99714 2/20 0.44
MAPK1 P28482 2/20 0.44
HPGD P15428 2/20 0.44
ATM Q13315 1/20 0.44
KDM4E B2RXH2 1/20 0.44
USP2 O75604 1/20 0.44
HTT P42858 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
TP53 P04637 2/20 0.43
RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6747003 0.86 TP53 (0.44) ALDH1A1MAPTLMNAPOLBKDM4E
SCHEMBL8345252 0.84 SMN1; SMN2 (0.52) GFERALDH1A1MAPTLMNAPOLB
SCHEMBL8343166 0.72 DRD2 (0.48) GFERALDH1A1MAPTLMNAGAA
SCHEMBL6678354 0.70 DRD2 (0.54) GFERALDH1A1MAPTLMNAPOLB
SCHEMBL6664679 0.68 SMN1; SMN2 (0.51) GFERALDH1A1MAPTPOLBDRD2
SCHEMBL6686372 0.67 ALDH1A1 (0.49) ALDH1A1MAPTPOLBDRD2MAPK1
SCHEMBL6664648 0.67 ALDH1A1 (0.49) ALDH1A1MAPTLMNAPOLBDRD2
SCHEMBL27312900 0.67 L3MBTL1 (0.44) ALDH1A1MAPTLMNAPOLBGAA
SCHEMBL6682842 0.67 ALDH1A1 (0.49) GFERALDH1A1MAPTPOLBDRD2
SCHEMBL6670427 0.67 ALDH1A1 (0.49) GFERALDH1A1MAPTLMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040043984-A1 3,4-Dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors O'BRIEN PATRICK MICHAEL (US) 2004-03-04 US claimed
WO-2004014389-A1 3,4-DIHYDROQUINOLIN-2-ONE, 5,6-FUSED OXAZIN-3-ONE, AND 5,6-FUSED THIAZIN-3-ONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO claimed
US-20040043984-A1 3,4-Dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors O'BRIEN PATRICK MICHAEL (US) 2004-03-04 US disclosed
WO-2004014389-A1 3,4-DIHYDROQUINOLIN-2-ONE, 5,6-FUSED OXAZIN-3-ONE, AND 5,6-FUSED THIAZIN-3-ONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed
WO-2004014389-A1 3,4-DIHYDROQUINOLIN-2-ONE, 5,6-FUSED OXAZIN-3-ONE, AND 5,6-FUSED THIAZIN-3-ONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043984-A1 3,4-Dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors MMP13, MMP9, MMP3 GFER 3483/4885ALDH1A1 675/4885MAPT 1797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.